The STRIVE Study: Breast Cancer Screening Cohort
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03085888|
Recruitment Status : Enrolling by invitation
First Posted : March 21, 2017
Last Update Posted : July 13, 2018
|Condition or disease|
|Invasive Breast Cancer Neoplasm, Breast Cancer, Breast|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||120000 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection|
|Actual Study Start Date :||February 28, 2017|
|Estimated Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||May 2025|
This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.
- Diagnosis of invasive breast cancer among women undergoing mammography [ Time Frame: 30 Months Estimated ]Clinically annotated plasma samples from participants will undergo high-intensity sequencing to characterize cfNA profiles.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03085888
Show 33 Study Locations
|Study Director:||Brian Allen, MS||GRAIL, Inc.|
|Study Director:||Anne-Renee Hartman, MD||GRAIL, Inc.|